Fortem Financial Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-110
Closed -$15K 436
2020
Q4
$15K Buy
+110
New +$14.1K 0.01% 325
2019
Q2
Sell
-7,506
Closed -$680K 162
2019
Q1
$680K Buy
7,506
+264
+4% +$22.5K 0.71% 50
2018
Q4
$520K Buy
+7,242
New +$583K 0.63% 51

Other funds holding XBI

Fortem Financial Group's XBI Position: Q1 2021 in Review

Fortem Financial Group sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2021, closing a stake of 110 shares — an estimated $15K sold.

Fortem Financial Group first reported a position in XBI in Q4 2018 and held it in 3 quarters. The position peaked at $680K in Q1 2019. 644 funds tracked by Wall St. Rank hold XBI as of Q1 2021.

  • Fortem Financial Group reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2021 after selling out during the quarter.
  • Fortem Financial Group sold 110 State Street SPDR S&P Biotech ETF shares in Q1 2021, an estimated $15K.
  • Fortem Financial Group first reported a position in State Street SPDR S&P Biotech ETF in Q4 2018 and held it in 3 quarters.
  • Fortem Financial Group's State Street SPDR S&P Biotech ETF position peaked at $680K in Q1 2019.
  • 644 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2021.

Based on Fortem Financial Group's 13F filing for Q1 2021, filed 20 Apr 2021.